Moderna Receives MHRA Authorization for Updated COVID-19 Vaccine Targeting JN.1 Variant

Moderna, Inc. announced on September 3, 2024, that the Medicines and Healthcare products Regulatory Agency (MHRA) has authorized its updated COVID-19 vaccine targeting the JN.1 variant of SARS-CoV-2. The JN.1 subvariant remains dominant in the UK.

The vaccine will be available for eligible groups through the NHS autumn vaccination program. For the first time, it will also be available for private purchase in the UK, sold at high street pharmacies, occupational health providers, and private healthcare companies.

The MHRA's decision aligns with the WHO Technical Advisory Group's recommendation to target the JN.1 family of Omicron subvariants for the 2024/25 campaign, reflecting current public health strategies.

Darius Hughes, UK General Manager of Moderna, emphasized the importance of updated vaccines in protecting those at greatest risk of severe illness and reducing strain on healthcare systems.